Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.

Chemotherapy-induced peripheral neuropathy, the numbness, tingling, and nerve pain many cancer patients experience after certain chemotherapy drugs, can be hard to treat and often lingers after treatment ends. This review pooled data from 16 randomized controlled trials testing exercise programs against usual care in cancer patients with this condition, looking at pain, physical function, and quality of life. The pooled results showed exercise groups had better quality of life, less neuropathic pain, stronger upper and lower limb muscles, and better balance than usual care groups, all statistically significant differences. However, the abstract specifically notes no evidence that exercise improved the core neuropathy symptoms themselves, a notable gap given the condition's defining features.

The usual care comparison, with less structured attention than an active exercise program, means some benefit could reflect factors beyond exercise itself, and the authors call for further work on exercise prescriptions to address this unresolved outcome.

If you've gone through chemotherapy and dealt with the numbness, tingling, or pain in your hands and feet known as chemotherapy-induced peripheral neuropathy, you know how much it can affect daily life. Researchers looked at 16 studies that tested whether structured exercise programs helped people with this condition, comparing them to patients who just received usual care. The combined results showed people doing exercise reported better quality of life, less neuropathic pain, stronger muscles in both arms and legs, and better balance than those receiving usual care.

These were meaningful, statistically significant differences across the pooled studies. However, the researchers did not find evidence that exercise improved the specific neuropathy symptoms themselves, like numbness or tingling, which is an important distinction.

Since the comparison group just received usual care rather than a similarly engaging activity, some of the benefit might partly reflect extra attention or engagement rather than exercise alone. The exact right type and amount of exercise for this condition still isn't established.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

For physiotherapists working with cancer patients managing chemotherapy-induced peripheral neuropathy, this meta-analysis of 16 randomized controlled trials addresses whether exercise interventions improve outcomes relevant to this population, specifically quality of life, physical function, and neuropathic pain, compared with usual care. The pooled analyses found statistically significant improvements in quality of life (SMD 0.83, 95% CI 0.58 to 1.08), neuropathic pain (MD -4.93, 95% CI -5.60 to -4.26), upper limb strength (SMD 1.10), lower limb strength (SMD 0.84), and balance (SMD 1.05), all with low to moderate heterogeneity (I2 0-36%). Notably, the abstract reports no evidence that exercise improved core CIPN symptoms, which is the outcome most directly tied to the neuropathy diagnosis itself; this distinction matters when counseling patients, since functional and quality-of-life gains should not be conflated with symptom resolution.

Because comparison groups received usual care rather than a matched active control, the attention and structure inherent to supervised exercise programs may partly explain some patient-reported benefits. The review does not specify optimal exercise type, dose, or duration, and the authors explicitly call for further exploration of exercise prescriptions, meaning this evidence informs that exercise broadly benefits function and quality of life in this population without yet establishing a specific protocol for CIPN symptom relief itself.